Supernus Pharmaceuticals, INC 8-K filings

Supernus Pharmaceuticals' ONAPGO (apomorphine hydrochloride) receives FDA approval as the first and only subcutaneous apomorphine infusion device for treating motor fluctuations in adults with advanced Parkinson's disease.

Supernus Pharmaceuticals receives FDA approval for a Qelbree label update, including new pharmacodynamic data and information for breastfeeding women.

Supernus Pharmaceuticals has updated its Code of Ethics and Business Conduct to clarify reporting channels, address conflicts of interest, and ensure compliance with laws and regulations.

Supernus Pharmaceuticals announced a 14% increase in total revenue for Q3 2024, driven by strong sales of Qelbree and GOCOVRI, and raised its full-year financial guidance.

Supernus Pharmaceuticals reports promising early results from a Phase 2a trial of SPN-820, showing rapid and significant improvement in depression symptoms in adults with major depressive disorder.

Supernus Pharmaceuticals will release its third quarter 2024 financial results after market close on November 4, 2024, followed by a conference call and webcast.

Supernus Pharmaceuticals reports promising results from a Phase 2a study of SPN-820, showing rapid and substantial reduction in depressive symptoms in adults with major depressive disorder.

Supernus Pharmaceuticals will host a webcast on October 17, 2024, to discuss the results of its Phase 2a study of SPN-820 for major depressive disorder.

Supernus Pharmaceuticals has announced the FDA has accepted the resubmission of its new drug application for its apomorphine infusion device, with a target action date set for February 1, 2025.

Supernus Pharmaceuticals announced a 24% increase in total revenue for the second quarter of 2024, driven by strong sales of Qelbree and GOCOVRI, and raised its full-year financial guidance.

Supernus Pharmaceuticals has resubmitted its New Drug Application for SPN-830, an apomorphine infusion device, aimed at treating motor fluctuations in Parkinson's disease, after addressing FDA concerns.

Supernus Pharmaceuticals will release its second quarter 2024 financial results after market close on August 6, 2024, followed by a conference call.

Supernus Pharmaceuticals held its annual meeting on June 14, 2024, electing directors, approving executive compensation, ratifying the accounting firm, and amending the equity incentive plan.

Supernus Pharmaceuticals reported promising interim data from a Phase 2a study of SPN-817, showing significant seizure reduction in patients with treatment-resistant epilepsy.

Supernus Pharmaceuticals will host a webcast on May 23, 2024, to discuss interim results from a Phase IIa study of SPN-817 for treatment-resistant seizures.

Supernus Pharmaceuticals announced a 75% increase in Qelbree net sales, contributing to a 12% rise in total revenue excluding legacy products, while reiterating its full-year financial guidance.

Supernus Pharmaceuticals will release its first quarter 2024 financial results after market close on May 8, 2024, followed by a conference call.

John M. Siebert, Ph.D., will retire from Supernus Pharmaceuticals' Board of Directors at the company's Annual Meeting in June 2024.

Supernus Pharmaceuticals has received a Complete Response Letter from the FDA regarding its New Drug Application for SPN-830, an apomorphine infusion device for Parkinson's disease.

Supernus Pharmaceuticals has increased the base salaries and awarded bonuses and stock options to its executive officers, effective January 1, 2024.

Supernus Pharmaceuticals announced its fourth quarter and full year 2023 financial results, highlighting significant growth in Qelbree sales but an overall decrease in total revenue due to declining sales of Trokendi XR.

Supernus Pharmaceuticals reports the retirement of Tami T. Martin, Senior Vice President of Regulatory Affairs, effective May 3, 2024, and the appointment of Roman Bradel as her successor in March 2024.

Supernus Pharmaceuticals will release its fourth quarter and full year 2023 financial results after market close on February 27, 2024, followed by a conference call.

Supernus Pharmaceuticals successfully defended its Trokendi XR patents against infringement by Torrent Pharmaceuticals, as ruled by the U.S. District Court for the District of New Jersey.